Agios Pharmaceuticals Inc.

# Signal Note: Rock Springs Capital Initiates AGIO Position Rock Springs' $21.8M entry into AGIO likely reflects conviction in the company's rare disease pipeline, particularly mitapivat (PYRUKYND) for pyruvate kinase deficiency, which gained FDA approval in 2021 and is generating early commercial traction. The timing suggests positioning ahead of potential near-term catalysts including expanded label data, international approvals, or updated financial guidance that could validate the franchise's revenue ramp. As a healthcare specialist with a concentrated mandate, Rock Springs' initiation signals they see asymmetric risk/reward in AGIO's pipeline execution relative to current valuation.